Meet the Minds
Behind Your Care
Our network comprises Directors of Hematology, CAR-T Pioneers, and Stem Cell experts from China's elite Grade 3A academic hospitals. When you submit your case, it is reviewed by a multidisciplinary board of these global authorities.
Leading Hematology & Cellular Therapy Experts
These distinguished professors lead the departments at our partner institutions. They serve as Principal Investigators (PIs) for groundbreaking CAR-T and stem cell trials.
Prof. Yafei Wang
Prof. Mingzhe Han
Prof. Shao Zonghong
Prof. Peng Zhao
Dr. Wei Hui
Prof. Xiangcheng Zhi
Frequently Asked Questions
Understanding our medical network and how we collaborate
No. CancerCareE is an access coordination platform, not a hospital. These distinguished professors and directors are employed by their respective Grade 3A academic hospitals in China (e.g., Tianjin Medical University Cancer Hospital, CAMS). We facilitate direct, formal consultations and Tumor Board reviews between you, your local oncologist, and these experts.
An MTB is a meeting where specialists from different fields (hematology, pathology, radiology, cellular therapy) review your specific case together to reach a consensus on the best treatment pathway. When you submit your case to CancerCareE, it is presented to an MTB comprising these leading experts.
Yes. Once your medical records are translated and formatted, we arrange secure, direct PI-to-PI (Principal Investigator to Principal Investigator) or patient-to-PI video consultations. Our medical coordinators provide real-time professional medical translation.
Submit Your Case to the Tumor Board
Don't rely on a single opinion. Let our network of Grade 3A directors and cellular therapy pioneers review your pathology, imaging, and treatment history. Free, confidential, and completed within 48 hours.
Start Free Case Review